Results 31 to 40 of about 3,148,135 (237)

Bullous fixed drug eruption due to erlotinib: A rare case report

Annals of Oncology Research and Therapy
Fixed Drug Eruption is one of the most common cutaneous adverse drug reactions, of which the bullous variant is a more severe form. Epidermal growth factor (EGFR) inhibitors are one of the prime chemotherapeutic agents used recently in various ...
Kallolinee Samal, Manoj Kumar Nayak, Srigopal Mohanty, Nibedita Dixit   +3 more
doaj   +1 more source

Advancing Environmental Sustainability: The Role of Artificial Intelligence in Monitoring, Predicting, and Controlling Sulfur Dioxide Emissions

Asia-Pacific Journal of Chemical Engineering, EarlyView.
ABSTRACT Air pollution from sulfur dioxide (SO2) emissions poses significant threats to environmental sustainability, public health, and climate change efforts. Despite advances in monitoring and regulatory frameworks, traditional methods often fall short in accuracy, scalability, and efficiency.
Turkan Kopac
wiley   +1 more source

Fixed Drug Eruption of the Penis Due to Hydroxyzine Hydrochloride

, 1997
Objective To report four cases of fixed drug eruption induced by hydroxyzine hydrochloride (Otarex, Teva, Israel). Case Summary Four children with restlessness who were treated with hydroxyzine hydrochloride developed fixed drug eruption of the penis ...
Asher Barzilai, Liora Harel, Herman Avner Cohen, Andre Matalon, Samuel Gross   +4 more
core   +1 more source

Piroxicam‐induced fixed drug eruption in palatal mucosa

, 2021
Background: Fixed drug eruption is a drug reaction characterized by the recurrent occurrence of erosive or ulcerative lesions in skin or mucosa surfaces upon the use of a specific drug. The occurrence of fixed drug eruption in oral mucosa is rare and ill
Saygo Tomo, da Silva Cunha, John L., Simonato, Luciana E., da Silva Santos, Ingrid, Ingrid da Silva Santos, Luciana E. Simonato, Ana C. Prado Ribeiro, Tomo, Saygo, dos Santos Silva, Alan R., Miyahara, Glauco I. [UNESP], Prado Ribeiro, Ana C., John L. da Silva Cunha, Glauco I. Miyahara, Alan R. dos Santos Silva   +13 more
core   +1 more source

A Pragmatic Trial of a Shared Decision‐Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The HCQ‐SAFE Study

Arthritis &Rheumatology, EarlyView.
Objective Hydroxychloroquine (HCQ) nonadherence in systemic lupus erythematosus (SLE) stemming from decision complexities can be improved with shared decision‐making (SDM) tools clarifying benefits and harms. This study aimed to develop and evaluate HCQ‐SAFE, a pictogram‐based SDM tool during SLE visits.
Caroline Packee, Jay J. Patel, Jessica Kent, Betty Chewning, Sancia Ferguson, Patricia Tellez‐Giron, David Gazeley, Christie M. Bartels, Shivani Garg   +8 more
wiley   +1 more source

Clinical Features and Drug Characteristics of Patients with Generalized Fixed Drug Eruption in the West of Iran (2005–2014)

Dermatology Research and Practice, 2015
Background. Generalized fixed drug eruption is a specific variant of fixed drug eruption with multifocal lesions. Diagnosis of this drug reaction is straightforward, but occasionally recognition of the causative drug is not possible. This study was aimed
Hossein Kavoussi, Mansour Rezaei, Katayoun Derakhshandeh, Alireza Moradi, Ali Ebrahimi, Harif Rashidian, Reza Kavoussi   +6 more
doaj   +1 more source

Evaluating a virtual paediatric adverse drug reaction clinic

British Journal of Clinical Pharmacology, EarlyView.
Aims Adverse drug reactions (ADRs) are a common problem in paediatric health care. There is limited access to expertise in the evaluation and management of potential ADRs in children, limiting access to these services and creating delays in assessment and management.
Emily Hauck, Blanca Del Pozzo‐Magana, Michael Rieder   +2 more
wiley   +1 more source

A case of entecavir-associated bullous fixed drug eruption and a review of literature

The Turkish Journal of Gastroenterology, 2019
Fixed drug eruption (FDE) is a type of drug reaction characterized by localized erythema, hyperpigmentation, and bullous at the same site(s), generally observed following every intake of a causative drug. Delayed-type cellular hypersensitivity (Type IVC)
Selami Aykut Temiz, İlkay Özer, Arzu Ataseven, Sıddıka Fındık   +3 more
doaj   +1 more source

HLA‐B*15:21 carrier status is a susceptibility factor of carbamazepine‐induced nonimmediate cutaneous adverse reactions in HLA‐B*15:02‐negative patients: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
After HLA‐B*15:02 screening, the residual risk of carbamazepine‐induced nonimmediate cutaneous adverse reactions is 0.059. Among these HLA‐B*15:02‐negative cases, HLA‐B*15:11 and HLA‐B*15:21 carrier status significantly increases the risk of carbamazepine‐induced nonimmediate cADR.
Warit Ruanglertboon, Chutima Seree‐aphinan, Antida Sangiemchoey, Khwanchanok Kaewpiboon, Taweesak Maneerot, Oradawan Plong‐on, Pornsiri Sangmanee, Punthipa Nichanon, Jariya Khayman, Jiraphan Manee, Areerat Hnoonual, Kanoot Jaruthamsophon   +11 more
wiley   +1 more source

Fixed drug eruption due to clarithromycin

Journal of Research in Pharmacy Practice, 2013
Fixed drug eruption (FDE) is an unusual adverse effect of any drug, especially antibiotics like clarithromycin. Herein we report a case of clarithromycin induced FDE in a 30-year-old man who presented with recurrent erythematous and pruritic cutaneous ...
Santoshi Balkrishna Malkarnekar, L Naveen   +1 more
doaj   +1 more source